PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis

다국어 초록 (Multilingual Abstract)

Purpose: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers.
Methods: A total of 100 HER2-positive breast cancer patients who had undergone NAC and surgery between 2004 and 2016 were examined. Mutation status was sequentially assessed in pre-NAC, post-NAC, and recurrent specimens taken from these patients. Results: PIK3CA mutations were identified in the sequential specimens of 17 patients (17.0%). These 17 patients experienced shorter disease-free survival (DFS) than the rest of the patients (58.3 months vs. 119.3 months, p=0.020); however, there was no significant difference in pathologic complete response (pCR) and overall survival (OS) (pCR, 17.6% vs. 33.7%, p=0.191; OS, 84.5 months vs. 118.0 months, p=0.984). While there was no difference in pCR between the wild-type and mutant PIK3CA groups in pre-NAC specimens (25.0% vs. 31.8%, p=0.199), PIK3CA mutations correlated with lower pCR in post- NAC specimens (0.0% vs. 24.3%, p<0.001). Multivariate analysis revealed significantly worse DFS in the mutant PIK3CA group than in the wild-type group (hazard ratio, 3.540; 95% confidence interval, 1.001–12.589; p=0.050). Moreover, the DFS curves of the change of PIK3CA mutation status in sequential specimens were significantly different (p=0.016). Conclusion: PIK3CA mutation in HER2-positive breast cancer was correlated with a lower pCR rate and shorter DFS. These results suggest that PIK3CA mutation is a prognostic marker for NAC in HER2-positive breast cancer, especially in post-NAC specimens.

참고문헌 (Reference)

1 Wang Y, "The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA)mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis" 29 : 633-642, 2013

2 Ibrahim EM, "The predictive and prognostic role of phosphatase phosphoinositol-3(PI3)kinase(PIK3CA)mutation in HER2-positive breast cancer receiving HER2-targeted therapy : a meta-analysis" 152 : 463-476, 2015

3 Engels CC, "The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population : a FOCUS study analysis" 156 : 361-370, 2016

4 Bachman KE, "The PIK3CA gene is mutated with high frequency in human breast cancers" 3 : 772-775, 2004

5 Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update" 31 : 3997-4013, 2013

6 Tolaney S, "Phase I/II study of pilaralisib(SAR245408)in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer" 149 : 151-161, 2015

7 Goel S, "PIK3CA mutations in HER2-positive breast cancer : an ongoing conundrum" 27 : 1368-1372, 2016

8 Loibl S, "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer : pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab" 27 : 1519-1525, 2016

9 Majewski IJ, "PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer" 33 : 1334-1339, 2015

10 Kalinsky K, "PIK3CA mutation associates with improved outcome in breast cancer" 15 : 5049-5059, 2009

11 Wang L, "PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib" 11 : 248-, 2011

12 Cizkova M, "Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab" 108 : 1807-1809, 2013

13 Yang SX, "New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer" 45 : 87-96, 2016

14 Loibl S, "Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)" 85 : 133-145, 2017

15 Mills GB, "Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer" 30 (30): 93-104, 2003

16 Xu BH, "Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer:efficacy, safety, and biomarker results from Chinese patients" 30 : 327-335, 2011

17 Toi M, "Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies" 101 : 1676-1682, 2009

18 Pogue-Geile KL, "Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial" 33 : 1340-1347, 2015

19 Toomey S, "Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response(pCR)in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies" 19 : 87-, 2017

20 Hennessy BT, "Exploiting the PI3K/AKT pathway for cancer drug discovery" 4 : 988-1004, 2005

21 Rexer BN, "Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells" 16 : R9-, 2014

22 Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours" 490 : 61-70, 2012

23 Yuan H, "Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast cancer" 21 : 4365-4372, 2015

24 Stemke-Hale K, "An integrative genomic and proteomic analysis of PIK-3CA, PTEN, and AKT mutations in breast cancer" 68 : 6084-6091, 2008

25 Hammond ME, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer" 28 : 2784-2795, 2010

26 Berns K, "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer" 12 : 395-402, 2007